Asia Pacific Benign Prostatic Hyperplasic Devices Market

The benign prostatic hyperplasic devices market in Asia Pacific is expected to grow from US$ 484.08 million in 2022 to US$ 771.09 million by 2028; it is estimated to grow at a CAGR of 8.1% from 2022 to 2028.

The benign prostatic hyperplasic devices market includes many small and big companies, which are adopting various strategies to improve their market shares. These strategies include new product launches, regional expansions, and technological advancements. With continued innovation, benign prostatic hyperplasic devices are becoming safer, and treatments are becoming easier and more effective than ever. This is driving the acceptance of benign prostatic hyperplasic devices across the region. In April 2022, Teleflex Incorporated launched the UroLift System in Japan for treating BPH or enlarged prostate. The system was made available for purchase immediately after the launch. Further, in May 2020, Teleflex Incorporated received National Medical Products Administration (NMPA) approval for its UroLift System for treating BPH in China. In April 2020, Olympus announced the approval of iTind, a nonsurgical medical device, for the minimally invasive surgery of BPH. This is a temporarily urethral opening device that has been given a De Novo classification by the FDA and is a Class II medical device. In July 2020, Sonablate, a global leader in minimally invasive ultrasound technology, received the NMPA clearance for its minimally invasive device to treat BPH. The device was earlier approved for the treatment of local, low- and medium-risk prostate cancer in China. Later, it was approved for the treatment of BPH in the country. The active participation of market players in product innovation and development, and an increase in the approvals of products are likely to fuel the growth of the benign prostatic hyperplasic devices market in Asia Pacific during the forecast period.

Asia Pacific Benign Prostatic Hyperplasic Devices Market Revenue and Forecast to 2028 (US$ Million)  

Asia Pacific Benign Prostatic Hyperplasic Devices Strategic Insights

Strategic insights for the Asia Pacific Benign Prostatic Hyperplasic Devices provides data-driven analysis of the industry landscape, including current trends, key players, and regional nuances. These insights offer actionable recommendations, enabling readers to differentiate themselves from competitors by identifying untapped segments or developing unique value propositions. Leveraging data analytics, these insights help industry players anticipate the market shifts, whether investors, manufacturers, or other stakeholders. A future-oriented perspective is essential, helping stakeholders anticipate market shifts and position themselves for long-term success in this dynamic region. Ultimately, effective strategic insights empower readers to make informed decisions that drive profitability and achieve their business objectives within the market.

Asia Pacific Benign Prostatic Hyperplasic Devices Report Scope

Asia Pacific Benign Prostatic Hyperplasic Devices Regional Insights

The geographic scope of the Asia Pacific Benign Prostatic Hyperplasic Devices refers to the specific areas in which a business operates and competes. Understanding local distinctions, such as diverse consumer preferences (e.g., demand for specific plug types or battery backup durations), varying economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved areas or adapting their offerings to meet local demands. A clear market focus allows for more effective resource allocation, targeted marketing campaigns, and better positioning against local competitors, ultimately driving growth in those targeted areas.

Asia Pacific Benign Prostatic Hyperplasic Devices Market Segmentation

The Asia Pacific benign prostatic hyperplasic devices market is segmented on the basis of product, procedure type, end user, and country. Based on product, the market is segmented into resectoscopes, urology lasers, radiofrequency ablation devices, prostatic stents, and implants. The resectoscopes segment is expected to hold the largest share of the market in 2022. On the other hand, the urology lasers segment is expected to register the highest CAGR during the forecast period. Based on procedure type, the Asia Pacific benign prostatic hyperplasic devices market is segmented into transurethral microwave therapy, transurethral resection of the prostate, transurethral needle ablation of the prostate, laser surgery, urolift surgery, and others. The transurethral resection of the prostate segment held the largest market share in 2022, and it is also expected to register the highest CAGR in the market during the forecast period. Based on end user, the Asia Pacific benign prostatic hyperplasic devices market is segmented into hospitals, clinics, ambulatory surgical centers, and others. The hospital segment held the largest market share in 2022, while the clinics segment is expected to register the highest CAGR during the forecast period. Based on country, the Asia Pacific benign prostatic hyperplasic devices market is segmented into China, Japan, India, Australia, South Korea, and Rest of Asia Pacific. In 2022, China held a larger market share. On the other side, and India is expected to register a higher CAGR during the forecast period.

KARL STORZ SE & Co. KG; Olympus Corporation; Boston Scientific Corporation; Teleflex Incorporated; and Richard Wolf GmbH are among the leading companies in the Asia Pacific benign prostatic hyperplasic devices market.